<?xml version="1.0" encoding="UTF-8"?>
<p>Treatment safety will be determined in close consultation with the DSMB. In case of SAEs related to the treatment, a follow-up trial will not be commenced. To establish the presence of a causal relationship to the study treatment, the WHOÂ guideline for pharmacovigilance will be followed.</p>
